Literature DB >> 24818719

The role of inflammation in inflammatory breast cancer.

Tamer M Fouad1, Takahiro Kogawa, James M Reuben, Naoto T Ueno.   

Abstract

Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer. Despite extensive study, whether inflammation contributes to the tumorigenicity or aggressiveness of IBC remains largely unknown. In this chapter, we will review the potential role played by inflammation in IBC based on the results of in vitro, in vivo, and patient studies. Current evidence suggests that several major inflammatory signaling pathways are constitutively active in IBC and breast cancer. Among them, the NF-κB, COX-2, and JAK/STAT signaling systems seem to play a major role in the tumorigenesis of IBC. Inflammatory molecules such as interleukin-6, tumor necrosis factor alpha (TNF-α), and gamma interferon have been shown to contribute to malignant transformation in preclinical studies of IBC, while transforming growth factor-β, interleukins 8 and 1β, as well as TNF-α appear to play a role in proliferation, survival, epithelial-mesenchymal transition, invasion, and metastasis. In this chapter, we also describe work thus far involving inhibitors of inflammation in the development of prevention and treatment strategies for IBC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24818719     DOI: 10.1007/978-3-0348-0837-8_3

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  21 in total

1.  Diabetes, Abnormal Glucose, Dyslipidemia, Hypertension, and Risk of Inflammatory and Other Breast Cancer.

Authors:  Catherine Schairer; Shahinaz M Gadalla; Ruth M Pfeiffer; Steven C Moore; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-01-13       Impact factor: 4.254

Review 2.  Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.

Authors:  Tamer M Fouad; Angelica M Gutierrez Barrera; James M Reuben; Anthony Lucci; Wendy A Woodward; Michael C Stauder; Bora Lim; Sarah M DeSnyder; Banu Arun; Babiera Gildy; Vicente Valero; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Lancet Oncol       Date:  2017-04       Impact factor: 41.316

3.  Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer.

Authors:  Naoto T Ueno; Savitri Krishnamurthy; Jennifer A Wargo; Elizabeth A Mittendorf; Sangeetha M Reddy; Alexandre Reuben; Souptik Barua; Hong Jiang; Shaojun Zhang; Linghua Wang; Vancheswaran Gopalakrishnan; Courtney W Hudgens; Michael T Tetzlaff; James M Reuben; Takahiro Tsujikawa; Lisa M Coussens; Khalida Wani; Yan He; Lily Villareal; Anita Wood; Arvind Rao; Wendy A Woodward
Journal:  Cancer Immunol Res       Date:  2019-05-01       Impact factor: 11.151

Review 4.  BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment.

Authors:  Guillaume P Andrieu; Jordan S Shafran; Jude T Deeney; Kishan R Bharadwaj; Annapoorni Rangarajan; Gerald V Denis
Journal:  J Leukoc Biol       Date:  2018-03-01       Impact factor: 4.962

5.  Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

Authors:  Herbert I Hurwitz; Nikhil Uppal; Stephanie A Wagner; Johanna C Bendell; J Thaddeus Beck; Seaborn M Wade; John J Nemunaitis; Philip J Stella; J Marc Pipas; Zev A Wainberg; Robert Manges; William M Garrett; Deborah S Hunter; Jason Clark; Lance Leopold; Victor Sandor; Richard S Levy
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

6.  BRCA mutations in women with inflammatory breast cancer.

Authors:  Angelica M Gutierrez Barrera; Tamer M Fouad; Juhee Song; Rachel Webster; Nisreen Elsayegh; Anita L Wood; Atakan Demir; Jennifer K Litton; Naoto T Ueno; Banu K Arun
Journal:  Cancer       Date:  2017-10-17       Impact factor: 6.860

Review 7.  Inflammatory breast cancer: no longer an absolute contraindication for breast conservation surgery following good response to neoadjuvant therapy.

Authors:  Monika Brzezinska; J Michael Dixon
Journal:  Gland Surg       Date:  2018-12

Review 8.  A multi-targeted approach to suppress tumor-promoting inflammation.

Authors:  Abbas K Samadi; Alan Bilsland; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Anupam Bishayee; Asfar S Azmi; Bal L Lokeshwar; Brendan Grue; Carolina Panis; Chandra S Boosani; Deepak Poudyal; Diana M Stafforini; Dipita Bhakta; Elena Niccolai; Gunjan Guha; H P Vasantha Rupasinghe; Hiromasa Fujii; Kanya Honoki; Kapil Mehta; Katia Aquilano; Leroy Lowe; Lorne J Hofseth; Luigi Ricciardiello; Maria Rosa Ciriolo; Neetu Singh; Richard L Whelan; Rupesh Chaturvedi; S Salman Ashraf; H M C Shantha Kumara; Somaira Nowsheen; Sulma I Mohammed; W Nicol Keith; William G Helferich; Xujuan Yang
Journal:  Semin Cancer Biol       Date:  2015-05-05       Impact factor: 15.707

9.  Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors.

Authors:  François Bertucci; Laurys Boudin; Pascal Finetti; Christophe Van Berckelaer; Peter Van Dam; Luc Dirix; Patrice Viens; Anthony Gonçalves; Naoto T Ueno; Steven Van Laere; Daniel Birnbaum; Emilie Mamessier
Journal:  Oncoimmunology       Date:  2021-05-23       Impact factor: 8.110

10.  In vitro vascularized tumor platform for modeling tumor-vasculature interactions of inflammatory breast cancer.

Authors:  Manasa Gadde; Caleb Phillips; Neda Ghousifam; Anna G Sorace; Enoch Wong; Savitri Krishnamurthy; Anum Syed; Omar Rahal; Thomas E Yankeelov; Wendy A Woodward; Marissa N Rylander
Journal:  Biotechnol Bioeng       Date:  2020-07-21       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.